SCOTUS rules biosimilar applicants can provide notice before FDA approval
The Supreme Court in the Sandoz v Amgen biosimilar case has ruled that an injunction is not available under federal law and an applicant may provide notice before obtaining a licence from the FDA. The ruling is a win for Sandoz, but the case was remanded for the Federal Circuit to rule on whether an injunction is still available under state law
The Supreme Court has ruled on the process for approving
biosimilars under the Biologics Price Competition and
Innovation Act (BPCIA) for the first time, mostly siding with
Sandoz in its dispute with Amgen.
The court said an injunction is not...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.